AU2001283199A1 - Methods and compositions for the diagnosis and treatment of brown adipose cell disorders - Google Patents

Methods and compositions for the diagnosis and treatment of brown adipose cell disorders

Info

Publication number
AU2001283199A1
AU2001283199A1 AU2001283199A AU8319901A AU2001283199A1 AU 2001283199 A1 AU2001283199 A1 AU 2001283199A1 AU 2001283199 A AU2001283199 A AU 2001283199A AU 8319901 A AU8319901 A AU 8319901A AU 2001283199 A1 AU2001283199 A1 AU 2001283199A1
Authority
AU
Australia
Prior art keywords
diagnosis
compositions
treatment
methods
brown adipose
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2001283199A
Inventor
Ruth Gimeno
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Millennium Pharmaceuticals Inc
Original Assignee
Millennium Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Millennium Pharmaceuticals Inc filed Critical Millennium Pharmaceuticals Inc
Publication of AU2001283199A1 publication Critical patent/AU2001283199A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5091—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing the pathological state of an organism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2510/00—Detection of programmed cell death, i.e. apoptosis
AU2001283199A 2000-08-08 2001-08-08 Methods and compositions for the diagnosis and treatment of brown adipose cell disorders Abandoned AU2001283199A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US63495600A 2000-08-08 2000-08-08
US09/634,956 2000-08-08
PCT/US2001/024901 WO2002012887A2 (en) 2000-08-08 2001-08-08 Methods and compositions for the diagnosis and treatment of brown adipose cell disorders

Publications (1)

Publication Number Publication Date
AU2001283199A1 true AU2001283199A1 (en) 2002-02-18

Family

ID=24545824

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2001283199A Abandoned AU2001283199A1 (en) 2000-08-08 2001-08-08 Methods and compositions for the diagnosis and treatment of brown adipose cell disorders

Country Status (2)

Country Link
AU (1) AU2001283199A1 (en)
WO (1) WO2002012887A2 (en)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070111933A1 (en) * 2003-06-02 2007-05-17 Kopchick John J Diagnosis and treatment methods related to aging, especially of liver
DK1677735T3 (en) 2003-10-17 2014-10-27 Joslin Diabetes Center Inc METHODS AND COMPOSITIONS FOR MODULATING ADIPOCYTE FUNCTION
US20100150885A1 (en) 2005-06-01 2010-06-17 Joslin Diabetes Center, Inc. Methods and compositions for inducing brown adipogenesis
FR2938333A1 (en) * 2008-11-13 2010-05-14 Galderma Res & Dev MODULATORS OF CIDEA IN THE TREATMENT OF ACNE, SEBORRHEA DERMATITIS OR HYPERSEBORRHEA
US9044606B2 (en) 2010-01-22 2015-06-02 Ethicon Endo-Surgery, Inc. Methods and devices for activating brown adipose tissue using electrical energy
US8476227B2 (en) 2010-01-22 2013-07-02 Ethicon Endo-Surgery, Inc. Methods of activating a melanocortin-4 receptor pathway in obese subjects
US10080884B2 (en) 2014-12-29 2018-09-25 Ethicon Llc Methods and devices for activating brown adipose tissue using electrical energy
US10092738B2 (en) 2014-12-29 2018-10-09 Ethicon Llc Methods and devices for inhibiting nerves when activating brown adipose tissue

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6348573B1 (en) * 1998-04-27 2002-02-19 The Regents Of The University Of Michigan Compositions and methods for identifying apoptosis signaling pathway inhibitors and activators

Also Published As

Publication number Publication date
WO2002012887A3 (en) 2002-09-19
WO2002012887A2 (en) 2002-02-14

Similar Documents

Publication Publication Date Title
AU2001271973A1 (en) Compositions and methods for the diagnosis and treatment of disorders involving angiogenesis
AU2001278852A1 (en) Compositions and methods for the diagnosis and treatment of disorders involving angiogenesis
AU7722600A (en) Compositions and methods for the diagnosis and treatment of immune disorders
WO2003034984A9 (en) Compositions and methods for the diagnosis and treatment of inflammatory bowel disorders
WO2004016225A8 (en) Compositions and methods for the diagnosis and treatment of tumor
EP1571968A3 (en) Compositions and methods for the diagnosis and treatment of tumor
WO2004045516A9 (en) Compositions and methods for the diagnosis and treatment of tumor
AU4205100A (en) Methods and compositions for the treatment of pancreatitis
AU2001259758A1 (en) Interleukin-1 inhibitors in the treatment of diseases
WO2002086502A8 (en) Methods for the diagnosis and treatment of bone disorders
AU2003200740A1 (en) Compositions and methods for the treatment of tumor
AU2003200731A1 (en) Compositions and methods for the treatment of tumor
AU2495200A (en) Compositions and methods for the treatment of tumor
EP1572091A3 (en) Compositions and methods for the diagnosis and treatment of tumor
WO2004060270A8 (en) Compositions and methods for the diagnosis and treatment of tumor
AU2003213787A1 (en) Compositions and methods for the treatment of anorectal disorders
WO2003057160A8 (en) Compositions and methods for the diagnosis and treatment of tumor
ZA200301204B (en) Compositions and methods for the diagnosis and treatment of tumor
AU5309600A (en) Compositions and methods for the treatment and diagnosis of immune disorders
AUPR101600A0 (en) Compositions and methods for diagnosis and treatment of cardiovascular disorders
AU8678501A (en) Compositions and methods for the diagnosis and treatment of tumor
AU2001283199A1 (en) Methods and compositions for the diagnosis and treatment of brown adipose cell disorders
AU3434601A (en) Compositions and methods for the treatment of immune related diseases
AU2002226060A1 (en) Compositions containing gangliosides for use in the treatment of skin disorders
AU2001255730A1 (en) Methods and compositions for the treatment of cardiac indications